Switch theme
Sign up to access all valuation multiples
Devyser Diagnostics AB develops, manufactures and sells diagnostic solutions and analysis services to clinical laboratories in more than 65 countries. The products are used for advanced genetic testing in the hereditary disease, oncology and transplant fields, to enable targeted cancer treatment, the diagnosis of a large number of genetic diseases, and transplant patient follow-up.
2004
121
LTM Revenue $25.3M
LTM EBITDA -$0.9M
$174M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Devyser Diagnostics has a last 12-month revenue (LTM) of $25.3M and a last 12-month EBITDA of -$0.9M.
In the most recent fiscal year, Devyser Diagnostics achieved revenue of $22.4M and an EBITDA of -$2.7M.
Devyser Diagnostics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Devyser Diagnostics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $25.3M | XXX | $22.4M | XXX | XXX | XXX |
| Gross Profit | $20.8M | XXX | $17.8M | XXX | XXX | XXX |
| Gross Margin | 82% | XXX | 80% | XXX | XXX | XXX |
| EBITDA | -$0.9M | XXX | -$2.7M | XXX | XXX | XXX |
| EBITDA Margin | -4% | XXX | -12% | XXX | XXX | XXX |
| EBIT | -$3.5M | XXX | -$6.5M | XXX | XXX | XXX |
| EBIT Margin | -14% | XXX | -29% | XXX | XXX | XXX |
| Net Profit | -$3.9M | XXX | -$6.3M | XXX | XXX | XXX |
| Net Margin | -15% | XXX | -28% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Devyser Diagnostics's stock price is SEK 105 (or $11).
Devyser Diagnostics has current market cap of SEK 1.7B (or $180M), and EV of SEK 1.7B (or $174M).
See Devyser Diagnostics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $174M | $180M | XXX | XXX | XXX | XXX | $-0.23 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Devyser Diagnostics has market cap of $180M and EV of $174M.
Devyser Diagnostics's trades at 7.8x EV/Revenue multiple, and -63.8x EV/EBITDA.
Equity research analysts estimate Devyser Diagnostics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Devyser Diagnostics has a P/E ratio of -45.8x.
See valuation multiples for Devyser Diagnostics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $180M | XXX | $180M | XXX | XXX | XXX |
| EV (current) | $174M | XXX | $174M | XXX | XXX | XXX |
| EV/Revenue | 6.9x | XXX | 7.8x | XXX | XXX | XXX |
| EV/EBITDA | -183.0x | XXX | -63.8x | XXX | XXX | XXX |
| EV/EBIT | -49.0x | XXX | -26.9x | XXX | XXX | XXX |
| EV/Gross Profit | 8.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | -45.8x | XXX | -28.3x | XXX | XXX | XXX |
| EV/FCF | -17.6x | XXX | -13.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialDevyser Diagnostics's last 12 month revenue growth is 34%
Devyser Diagnostics's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.2M for the same period.
Devyser Diagnostics's rule of 40 is 10% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Devyser Diagnostics's rule of X is 82% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Devyser Diagnostics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 34% | XXX | 34% | XXX | XXX | XXX |
| EBITDA Margin | -4% | XXX | -12% | XXX | XXX | XXX |
| EBITDA Growth | -693% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 10% | XXX | 22% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 82% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 65% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 20% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 108% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Devyser Diagnostics acquired XXX companies to date.
Last acquisition by Devyser Diagnostics was XXXXXXXX, XXXXX XXXXX XXXXXX . Devyser Diagnostics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Devyser Diagnostics founded? | Devyser Diagnostics was founded in 2004. |
| Where is Devyser Diagnostics headquartered? | Devyser Diagnostics is headquartered in Sweden. |
| How many employees does Devyser Diagnostics have? | As of today, Devyser Diagnostics has 121 employees. |
| Who is the CEO of Devyser Diagnostics? | Devyser Diagnostics's CEO is Mr. Fredrik Alpsten. |
| Is Devyser Diagnostics publicy listed? | Yes, Devyser Diagnostics is a public company listed on STO. |
| What is the stock symbol of Devyser Diagnostics? | Devyser Diagnostics trades under DVYSR ticker. |
| When did Devyser Diagnostics go public? | Devyser Diagnostics went public in 2021. |
| Who are competitors of Devyser Diagnostics? | Similar companies to Devyser Diagnostics include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm. |
| What is the current market cap of Devyser Diagnostics? | Devyser Diagnostics's current market cap is $180M |
| What is the current revenue of Devyser Diagnostics? | Devyser Diagnostics's last 12 months revenue is $25.3M. |
| What is the current revenue growth of Devyser Diagnostics? | Devyser Diagnostics revenue growth (NTM/LTM) is 34%. |
| What is the current EV/Revenue multiple of Devyser Diagnostics? | Current revenue multiple of Devyser Diagnostics is 6.9x. |
| Is Devyser Diagnostics profitable? | Yes, Devyser Diagnostics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Devyser Diagnostics? | Devyser Diagnostics's last 12 months EBITDA is -$0.9M. |
| What is Devyser Diagnostics's EBITDA margin? | Devyser Diagnostics's last 12 months EBITDA margin is -4%. |
| What is the current EV/EBITDA multiple of Devyser Diagnostics? | Current EBITDA multiple of Devyser Diagnostics is -183.0x. |
| What is the current FCF of Devyser Diagnostics? | Devyser Diagnostics's last 12 months FCF is -$9.9M. |
| What is Devyser Diagnostics's FCF margin? | Devyser Diagnostics's last 12 months FCF margin is -39%. |
| What is the current EV/FCF multiple of Devyser Diagnostics? | Current FCF multiple of Devyser Diagnostics is -17.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
